International IgA Nephropathy Prediction Tool
Predicts risk of 50% decline in eGFR or end-stage kidney disease in patients with IgA nephropathy.
This calculator includes models which contain race as an input. Study authors have also developed a model which does not include race, making the input optional. See here for more on our approach to addressing race and bias on MDCalc.
-
All patients diagnosed with IgA nephropathy should receive optimized supportive care. This includes blood pressure control, reducing proteinuria with renin-angiotensin system blockade, lipid management, and lifestyle modifications. For some patients, sodium-glucose cotransporter 2 (SGLT2) inhibitors may also be appropriate.
-
The results of this tool may be used to guide discussions about treatment and prognosis with patients.
-
Patients identified as high-risk for disease progression may benefit from more aggressive treatment strategies, including immunosuppressive therapy. Conversely, low-risk patients might avoid the potential toxicity associated with unnecessary immunosuppression.
-
The risk assessment provided by this tool does not determine the likely impact of any particular treatment and should not be the sole determinant in treatment decisions. Other factors, such as patient characteristics, goals, response to supportive therapy, and treatment risks, should be considered.
- For more detailed treatment guidance, please see the KDIGO clinical practice guidelines for the management of glomerular diseases.